BioX­cel says in­de­pen­dent au­dit of Alzheimer’s study found mis­con­duct did not im­pact da­ta re­li­a­bil­i­ty

BioX­cel Ther­a­peu­tics said Wednes­day that it still plans to use da­ta from a site in its Phase III Alzheimer’s dis­ease study af­ter the FDA cit­ed the un­eth­i­cal be­hav­ior of one of the study’s in­ves­ti­ga­tors, who fab­ri­cat­ed an email when she re­port­ed a par­tic­i­pant’s se­ri­ous med­ical event.

Ac­cord­ing to BioX­cel, the in­de­pen­dent au­dit found that the da­ta it re­viewed from the site were a rep­re­sen­ta­tive sam­ple, and the au­di­tors “did not iden­ti­fy any find­ings that they be­lieve im­pact the da­ta re­li­a­bil­i­ty or in­tegri­ty, nor did they find any ev­i­dence of ad­di­tion­al mis­con­duct or fraud.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER